INSUBCONTINENT EXCLUSIVE:
Glenmark said its portfolio consists of 166 products authorised for distribution in United StatesGlenmark Pharma received final approval
from the United States Food and Drug Administration (USFDA) for Tacrolimus capsules, which are used as immunosuppressants to prevent the
human immune system from rejecting liver, kidney and heart transplants
The stock gained 1.7 per cent to touch an intra-day high of Rs 483 on the BSE in early trading on the back of the news development
the United States Food and Drug Administration (USFDA) for Tacrolimus Capsules USP in the strengths of 0.5 mg, 1 mg and 5 mg, Glenmark said
consists of 166 products authorised for distribution in the United States and 45 abbreviated new drug applications are pending approval with
the USFDA.The BSE Sensex was trading mildly in the positive at 43,338.90, up 0.1 per cent and NSE Nifty was at 12,666.55, up 0.2 per cent.
